The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.